Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | HTR3A | P46098 | 3/20 | 0.41 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.40 |
| ▸ | OXTR | P30559 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15216675 | 0.96 | HDAC3 (0.48) | HDAC3HDAC6NCOR2CA12CA1 | |
| SCHEMBL12185042 | 0.91 | HDAC3 (0.48) | HDAC3HDAC6NCOR2CA12CA1 | |
| SCHEMBL17452084 | 0.88 | HDAC3 (0.45) | HDAC3HDAC6NCOR2CA12CA1 | |
| SCHEMBL15216686 | 0.86 | CA12 (0.44) | CA12CA1CA2CA9CA14 | |
| SCHEMBL15218369 | 0.85 | CA1 (0.50) | CA12CA1CA2CA9CA14 | |
| SCHEMBL15216676 | 0.82 | CA1 (0.51) | CA12CA1CA2CA9CA14 | |
| SCHEMBL15216663 | 0.82 | CA1 (0.51) | CA12CA1CA2CA9CA14 | |
| SCHEMBL18720047 | 0.82 | CA1 (0.51) | CA12CA1CA2CA9CA14 | |
| SCHEMBL12185011 | 0.81 | HDAC3 (0.37) | HDAC3HDAC6NCOR2CA12CA1 | |
| SCHEMBL15216690 | 0.80 | HTR3A (0.43) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170102387-A1 | ZANAMIVIR PHOSPHONATE CONGENERS WITH ANTI-INFLUENZA ACTIVITY AND DETERMINING OSELTAMIVIR SUSCEPTIBILITY OF INFLUENZA VIRUSES | ACADEMIA SINICA (TW) | 2017-04-13 | — | — | US | disclosed |
| US-20130225532-A1 | ZANAMIVIR PHOSPHONATE CONGENERS WITH ANTI-INFLUENZA ACTIVITY AND DETERMINING OSELTAMIVIR SUSCEPTIBILITY OF INFLUENZA VIRUSES | ACADEMIA SINICA (TW) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225532-A1 | ZANAMIVIR PHOSPHONATE CONGENERS WITH ANTI-INFLUENZA ACTIVITY AND DETERMINING OSELTAMIVIR SUSCEPTIBILITY OF INFLUENZA VIRUSES | NEU1, NEU3, NEU4 | HDAC3 2771/4885HDAC6 2502/4885NCOR2 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.